论文部分内容阅读
TNK组织纤维蛋白溶酶原激活剂(TNK-TPA)是TPA的一种遗传生物工程变异型。该药在实验性模型中显示血浆清除缓慢、显著的纤维蛋白特异性和对抗纤维蛋白溶酶原激活剂抑制物-1较TPA强80倍以上。
TNK Tissue plasminogen activator (TNK-TPA) is a genetic bioengineered variant of TPA. The drug showed slow plasma clearance, significant fibrin specificity and anti-plasminogen activator inhibitor-1 more than 80-fold more potent than TPA in experimental models.